ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "registry"

  • Abstract Number: 0377 • ACR Convergence 2023

    Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis

    Melissa Mannion1, Monica Aswani2, Kristine Hearld2, Emily Smitherman2, Livie Huie3 and Jeffrey R Curtis4, 1University of Alabama at Brimingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Gardendale, AL, 4Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL

    Background/Purpose: The goal of treatment for patients with juvenile idiopathic arthritis (JIA) is inactive or minimal disease activity and escalating medication for active disease is…
  • Abstract Number: 1095 • ACR Convergence 2023

    Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures

    Emma Kersey1, Jing Li1, Julia Kay1, Julia Adler-Milstein1, Jinoos Yazdany2 and Gabriela Schmajuk3, 1University of California San Francisco, San Francisco, CA, 2University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 3UCSF / SFVA, San Francisco, CA

    Background/Purpose: The American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) EHR-based registry facilitates quality measure calculation and reporting for rheumatology practices in national…
  • Abstract Number: 1964 • ACR Convergence 2023

    Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization

    Jacob Colello1, Kirsten Riggle1, Galen Foulke2, Peri Newman1, Jamie Carter1 and Nancy Olsen1, 1TE-Penn State MS Hershey Medical Center, Hershey, PA, 2Penn State MS Hershey Medical Center, Hershey, PA

    Background/Purpose: Dermatomyositis (DM) is a relatively rare condition with significant morbidity and mortality across the lifespan.Recent advances in diagnostics and therapeutics have significant potential to…
  • Abstract Number: 0432 • ACR Convergence 2023

    Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice

    Rodolfo Perez-Alamino1, Carolina Isnardi2, Enrique Soriano3, Luciano Lo Giudice4, johana zacariaz hereter4, Gustavo Casado5, Victor Caputo5, Andrea Schmichowski5, Cecilia Romeo5, Estela Rivero5, Florencia Savy6, Mercedes García7, Olga Romano1, Hernan Maldonado Ficco8 and Gustavo Citera2, 1Hospital Avellaneda, Tucuman, Argentina, 2IREP, Buenos Aires, Argentina, 3Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Hospital Militar Central, Buenos Aires, Argentina, 6HIGA San Martin, La Plata, Argentina, 7Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, 8Hospital San Antonio de Padua, Río Cuarto, Argentina

    Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…
  • Abstract Number: 1134 • ACR Convergence 2023

    Pilot Study Investigating Adenosine Deaminase-2 as a Disease Activity Biomarker for Cardiac Sarcoidosis

    Jeffrey Shen1, Jayanth Doss1, Ravichandra Karra Gurunath1, Kelly Arps1, Megan Milne2, Rishi Rampersad1, Kees Frelinger1, Michael Hershfield1 and Teresa Tarrant1, 1Duke University, Durham, NC, 2Costal Carolina Health Care, New Bern, NC

    Background/Purpose: Sarcoidosis is a heterogenous granulomatous inflammatory disease that is especially dangerous when it affects the heart where it may cause fatal arrythmias and heart…
  • Abstract Number: 2114 • ACR Convergence 2023

    The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function

    Sho Fukui1, Wolfgang Winkelmayer2, Sara Tedeschi1, Javier Marrugo1, Hongshu Guan1, Leslie Harrold3, Heather Litman3, Tomohiro Shinozaki4 and Daniel Solomon5, 1Brigham and Women's Hospital, Boston, MA, 2Baylor College of Medicine, Houston, TX, 3CorEvitas, LLC, Waltham, MA, 4Tokyo University of Science, Tokyo, Japan, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
  • Abstract Number: 0447 • ACR Convergence 2023

    Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER

    Lucia Otero-Valera1, Jose María Alvaro-Gracias2, Jerusalem Calvo3, Cristina Campos4, Alicia Garcia Dorta5, Fernando Sánchez-Alonso6 and Isabel Castrejon7, 1Spanish Society of Rheumatology, Madrid, Spain, 2Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Reina Sofia University Hospital, Córdoba, Spain, 4Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, 5Rheumatology Unit, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 6Fundación Española de Reumatología, Madrid, Spain, 7Hospital Universitario Gregorio Marañón, Madrid, Spain

    Background/Purpose: Glucocorticoids are frequently used as bridging therapy for rheumatoid arthritis (RA) patients starting conventional synthetic DMARDs. Both EULAR and ACR guidelines (1,2), recommend to…
  • Abstract Number: 1182 • ACR Convergence 2023

    Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies

    Kristin Wipfler1, Michael Feely2, Gulsen Ozen3, Urbano Sbarigia4, Federico Zazzetti5, Anna Sheahan6, Iris Lin7, Evo Alemao8 and Kaleb Michaud2, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Nebraska Medical Center, Bellevue, NE, 4Janssen Pharmaceutica, Beerse, Belgium, 5Janssen Research & Development, LLC, Spring House, PA, 6Janssen, Raleigh, NC, 7Janssen, Horsham, PA, 8Janssen Pharmaceuticals, New Hope, PA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare, heterogeneous diseases characterized by chronic skeletal muscle inflammation and weakness. Initial conventional therapy is based on expert opinion…
  • Abstract Number: 2118 • ACR Convergence 2023

    New Onset Disability in Rheumatoid Arthritis Is an Underrecognized Cardiovascular Risk Factor: A Retrospective Cohort Study Using the CorEvitas Registry

    Robert Spandorfer1, Kevin Kane2, George Reed2, Dimitrios Pappas2, Joel Kremer2, Jeffrey Curtis3 and Iris Navarro-Millán4, 1Hospital for Special Surgery, Brooklyn, NY, 2CorEvitas, LLC, Waltham, MA, 3University of Alabama at Birmingham, Birmingham, AL, 4Weill Cornell Medicine, Hospital for Special Surgery, New York, NY

    Background/Purpose: Cardiovascular disease (CVD) is the most common cause of death among patients with RA. Prior research found a higher rate of CVD events associated…
  • Abstract Number: 0483 • ACR Convergence 2023

    The Influence of “Fibromyalgia-ness” on Treatment Response Amongst Patients with Psoriatic Arthritis (PsA). Results from the British Society for Rheumatology Psoriatic Arthritis Register (BSR‐PsA)

    Gary Macfarlane1, Ovidiu Rotariu2, Stephanie Lembke2, Flavia Sunzini3, Gareth T. Jones1 and Neil Basu3, 1Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, 2University of Aberdeen, Aberdeen, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Co-morbid fibromyalgia has been shown to be an important influence on non-response in patients with some inflammatory arthritides. Around 1 in 5 patients with…
  • Abstract Number: 1200 • ACR Convergence 2023

    Self-Reported Effectiveness of Cannabis for Arthritis-Related Pain

    Kristin Wipfler1, Joanna Zeiger2 and Kaleb Michaud3, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2Canna Research Foundation, Boulder, CO, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Pain management remains a significant challenge for individuals with rheumatic diseases (RDs), often causing patients to seek complementary or alternative treatments to traditional medications.…
  • Abstract Number: 2204 • ACR Convergence 2023

    Residual Disease Activity in Canadian Patients with Axial Spondyloarthritis: Results from a Multi-registry Analysis (UNISON-Axial SpA)

    Denis Choquette1, Walter P. Maksymowych2, Proton Rahman3, Robert Inman4, Marie-Claude Laliberté5, Pierre-Andre Fournier6, Tanya Girard5 and Dafna Gladman7, 1Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, 4University Health Network, Toronto, ON, Canada, 5AbbVie, Inc., Saint-Laurent, QC, Canada, 6AbbVie, Inc., Montréal, QC, Canada, 7Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: In patients with axial spondyloarthritis (axSpA), treatment goals consist of achieving remission or low disease activity (LDA) to alleviate symptoms, improve function, decrease disease…
  • Abstract Number: 0516 • ACR Convergence 2023

    Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry

    Casper Webers1, Rabab Nezam El-Din1, Marin Been1, Harald Vonkeman2 and Astrid van Tubergen1, 1Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, 2Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands

    Background/Purpose: In the management of axial spondyloarthritis (axSpA), treatment intensification (TI) is recommended in patients with high disease activity (HDA). However, in practice, in most…
  • Abstract Number: 1223 • ACR Convergence 2023

    Extracorporeal Life Support for Childhood-Onset Systemic Lupus Erythematosus: An ELSO Registry Analysis

    Carla Levin1, Andrea Ontaneda2, Danielle Guffey3, Peter Rycus4, Marc Anders2, Eyal Muscal5 and Maria Pereira5, 1Department of Pediatrics, Baylor College of Medicine, Houston, TX, 2Division of Critical Care, Department of Pediatrics, Baylor College of Medicine, Houston, TX, 3Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 4Extracorporeal Life Support Organization, Ann Arbor, MI, 5Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a heterogeneous multisystemic autoimmune disorder that can cause life-threatening complications. There is a paucity of data on the utility…
  • Abstract Number: 2222 • ACR Convergence 2023

    Association Spondyloarthritis and Inflammatory Bowel Disease, More Severe Diseases on Both Sides

    Juliane Michel1, Clément Prati2, Lucine Vuitton3, Eric Toussirot4, Charline Vauchy5, Daniel Wendling6 and frank Verhoeven2, 1Rheumatology, CHU Besancon, Besançon, France, 2Service de rhumatologie, CHU de Besançon, Besançon, France, 3Gastroenterology, CHU Besancon, Besançon, France, 4University Hospital of Besancon, Besançon, France, 5INSERM CIC-1431, Besançon, France, 6Besançon University Hospital, Besançon, France

    Background/Purpose: There is a pathophysiological link between spondyloarthritis (SpA) and Inflammatory Bowel Disease (IBD), so that 10% of IBD is estimated to have SpA and…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 18
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology